Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.…
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latigo Biotherapeutics (NASDAQ: LTGO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 13.00 USD on 20 November 2026. Its 52-week range is 10.45 USD to 25.93 USD: the price is 49.9% below the high and 24.4% above the low.
Its market capitalisation is 861.89M USD.
Latigo Biotherapeutics reports return on equity of 47.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 400.22M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 18 March 2027.